Novel rapid treatment options for adolescent depression

Pharmacological Research, Journal Year: 2024, Volume and Issue: 201, P. 107085 - 107085

Published: Feb. 2, 2024

There is an urgent need for novel fast-acting antidepressants adolescent treatment-resistant depression and/or suicidal risk, since the selective serotonin reuptake inhibitors that are clinically approved age (i.e., fluoxetine or escitalopram) take weeks to work. In this context, one of main research lines our group characterize at preclinical level approaches rapid-acting adolescence. The present review summarizes potential use in adolescence non-pharmacological options, such as neuromodulators (electroconvulsive therapy and other innovative types brain stimulation), well pharmacological including consciousness-altering drugs (mainly ketamine but also classical psychedelics) cannabinoids cannabidiol), with promising responses. Following a brief analytical explanation depression, we general introduction each therapeutical approach together clinical evidence supporting its beneficial extrapolated from prior successful examples adults), then report recent ongoing studies will aid improving inclusion these therapies clinic, by considering sex-, age-, dose-related differences, factors might affect efficacy long-term safety. Finally, conclude providing future avenues maximize treatment response, more importance designing testing options safe depression.

Language: Английский

---

Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts

Pain and Therapy, Journal Year: 2024, Volume and Issue: 13(5), P. 1063 - 1094

Published: Aug. 3, 2024

Interest in medical cannabis and cannabis-based medicinal products (CBMPs) has increased greatly recent years. Two cannabinoids are of principal importance; delta-9-tetrahydrocannabinol (∆9-THC), the primary psychoactive component, also cannabidiol (CBD), considered non-intoxicating. Each distinct mechanisms action different therapeutic potentials. CBMPs differ their ∆9-THC CBD components; predominantly ∆9-THC, balanced formulations with equivalent elements, CBD-predominant products. In this narrative review, we evaluate published evidence for clinical benefits overall well-being. We review safety profile discuss potential dependence CBMPs. Evidence can be drawn from a wide range randomized other controlled studies observational real-world studies. Most data registry supportive ∆9-THC-based (∆9-THC-predominant or CBMPs) management chronic neuropathic pain. Balanced effective reducing spasticity multiple sclerosis. show benefit providing symptomatic anxiety, nausea, improving sleep, but place specific is more subtle, choice guided by circumstances. Symptomatic improvements accompanied improved quality life Safety indicate that generally well tolerated most patients without contraindications. The majority adverse effects non-serious, transient; principally associated dose-dependent. contrast to recreational use, there little have any dependence.

Language: Английский

---

Virtual Care and Medical Cannabis Access: A Geospatial Study of Telehealth’s Role in Reducing Socioeconomic Disparities

Telemedicine Journal and e-Health, Journal Year: 2025, Volume and Issue: unknown

Published: March 11, 2025

Introduction: Telehealth has the potential to improve health care access and reduce disparities. We examined whether density of medical cannabis (MC) patients, stratified by those who were seen a telemedicine provider or not, is associated with concentrated disadvantage within Pennsylvania in 2022. Methods: This zip code-level analysis assessed associations between index (CDI) counts telemedicine-approved all other MC patients. Total patient obtained from Pennsylvania's Department Health, patients telehealth (Leafwell), CDI data 2022 American Community Survey. Multivariable negative binomial regression models population offsets robust standard errors used, accounting for spatial autocorrelation through lag adjustments. Results: The was not number (incidence rate ratios [IRR] = 0.962; p 0.355) but significantly negatively (IRR 0.904; <0.001). in-office providers count Spatial factors influenced distribution both groups. Discussion: These findings suggest that may play crucial role reducing disparities socioeconomically disadvantaged areas. lack significant association indicates services can overcome barriers such as scarcity transportation issues. By facilitating remote consultations approvals, expands might otherwise be unable obtain MC.

Language: Английский

---

The role of depression in the relationship between cannabis use and suicidal behaviours: a systematic review and meta-analysis

Drug and Alcohol Dependence, Journal Year: 2025, Volume and Issue: unknown, P. 112714 - 112714

Published: May 1, 2025

Language: Английский

---

Effectiveness of Medical Cannabis for the Treatment of Depression: A Naturalistic Outpatient Study

Pharmacopsychiatry, Journal Year: 2024, Volume and Issue: 57(02), P. 61 - 68

Published: Jan. 11, 2024

Abstract Background There is a lack of studies on the course and effectiveness medical cannabis in treatment major depressive disorder (MDD). Methods Retrospective longitudinal (18 weeks) study n=59 outpatients with MDD, treated via telemedical platform. Previous antidepressant medication was required for inclusion into study. Standardized data collection carried out at entry during monthly consultations. Severity depression measured 0–10 point rating scale. Side-effects were assessed by checklist. Results Patients 20–54 years old; 72.9% male; one third reported times regular consumption within previous five years. Drop-out rate 22% after 18 weeks. Mean severity decreased from 6.9 points (SD 1.5) to 3.8 (2.7) week (baseline observation forward; 95% CI mean difference: 2.4 3.8; p<0.001). A response (>50% reduction initial score) seen 50.8% 18. One patients complained about side effects, none considered as severe. Concomitant (31% patients) not associated outcome. Conclusions Medical well tolerated dropout comparable those clinical trials medication. clinically significant severity. Further research MDD seems warranted. Risks this medication, such sustaining or inducing use disorder, effects poor concentration, must be taken consideration.

Language: Английский

---

UK Medical Cannabis Registry: An analysis of clinical outcomes of medicinal cannabis therapy for attention‐deficit/hyperactivity disorder

Neuropsychopharmacology Reports, Journal Year: 2023, Volume and Issue: 43(4), P. 596 - 606

Published: Dec. 1, 2023

This study aims to analyze the health-related quality of life (HRQoL) and safety outcomes in attention-deficit/hyperactivity disorder (ADHD) patients treated with cannabis-based medicinal products (CBMPs).Patients were identified from UK Medical Cannabis Registry. Primary changes following patient-reported outcome measures (PROMs) at 1, 3, 6, 12 months baseline: EQ-5D-5L index value, generalized anxiety disorder-7 (GAD-7) questionnaire, single-item sleep score (SQS). Secondary assessed incidence adverse events. Statistical significance was defined as p < 0.050.Sixty-eight met inclusion criteria. Significant improvements general HRQoL by value 6 (p 0.050). Improvements also GAD-7 SQS scores 0.010). 61 (89.71%) events recorded 11 (16.18%) participants, which most moderate (n = 26, 38.24%).An association between CBMP treatment anxiety, quality, observed ADHD. Treatment well tolerated months. Results must be interpreted caution a causative effect cannot proven. These results, however, do provide additional support for future evaluation within randomized controlled trials.

Language: Английский

---

Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence

BJPsych Open, Journal Year: 2024, Volume and Issue: 10(2)

Published: March 1, 2024

Background Cannabis-based medicinal products (CBMPs) are increasingly being used to treat post-traumatic stress disorder (PTSD), despite limited evidence of their efficacy. PTSD is often comorbid with major depression, and little known about whether depression alters the effectiveness CBMPs. Aims To document prevalence among individuals seeking CBMPs examine varies by status. Method Data were available for 238 people CBMP treatment (5.9% treatment-seeking sample) 3-month follow-up data 116 these. Self-reported symptoms assessed at entry using Checklist – Civilian Version (PCL-C). The probable presence was nine-item Patient Health Questionnaire (PHQ-9). Additional included sociodemographic characteristics self-reported quality life. Results In total, 77% met screening criteria which associated higher levels symptomatology (mean 67.8 v. 48.4, F (1,236) = 118.5, P < 0.001) poorer general health, life sleep. reduced substantially 3 months after commencing 58.0 47.0, (1,112) 14.5, 0.001), a significant interaction ( 6.2, 0.05) indicating greater improvement in those difference 15.3) than without 7). Conclusions Depression common symptom severity Effectiveness treating does not appear be impaired depression.

Language: Английский

---

Changes in Pain and Mental Health Symptoms Associated with Prescribed Medicinal Cannabis Use: A One-Year Longitudinal Study

Journal of Pain & Palliative Care Pharmacotherapy, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 13

Published: Oct. 21, 2024

Chronic pain and mental health issues like depression anxiety significantly contribute to disease burden in Western countries. While cannabinoids are suggested have analgesic, anxiolytic antidepressant properties, evidence, especially for long-term use, is inconclusive. This 12-month observational study evaluated the effects of prescribed medicinal cannabis 96 patients suffering from pain, as well sleep disturbances, anxiety. Treatment outcomes depression, problems were assessed at 3, 6, 12 months using validated instruments. Significant reductions observed scores interference on daily functions, alongside improvements sleep. Many reported notable severity reduced use medications first 6 months, with a decline months. Additionally, sustained anxiety, stress observed, about half reporting substantial improvement. Adverse common but mostly mild or moderate, most commonly dry mouth sleepiness. These results show that treatment associated chronic symptoms, such stress. However, findings also suggest effectiveness longer-term emphasizing need additional research.

Language: Английский

---

UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients

International Clinical Psychopharmacology, Journal Year: 2024, Volume and Issue: 39(6), P. 350 - 360

Published: Feb. 1, 2024

This study aims to analyze changes in health-related quality of life (HRQoL) and safety patients with generalized anxiety disorder (GAD) prescribed a homogenous selection cannabis-based medicinal products (CBMPs). Patients Adven CBMPs (Curaleaf International, UK) for GAD were identified from the UK Medical Cannabis Registry. Primary outcomes patient-reported outcome measures (PROMs) baseline up 12 months, including GAD-7, Single-Item Sleep Quality Scale (SQS), EQ-5D-5L. Adverse events recorded using CTCAE version 4.0. A total 120 inclusion, which 38 (31.67%), 52 (43.33%), 30 (25.00%) oils, dried flower, both formulations CBMP. Associated improvements SQS, EQ-5D-5L at 1, 3, 6, months observed compared ( P < 0.010). There 24 (20.00%) who reported 442 (368.33%) adverse events, most mild (n = 184, 41.63%) moderate 197, 44.57%). reports an association between initiation homogeneous CBMP therapy severity HRQoL individuals GAD. Moreover, was well-tolerated follow-up. Further investigation through randomized controlled trials will ultimately be required determine causation.

Language: Английский

---

An observational study of clinical outcome measures in patients treated with cannabis‐based medicinal products on the UK Medical Cannabis Registry

Neuropsychopharmacology Reports, Journal Year: 2023, Volume and Issue: 43(4), P. 616 - 632

Published: Dec. 1, 2023

While there is increasing evidence of the effects cannabis-based medicinal products (CBMPs) on health-related quality life (HRQoL), a major limitation current literature heterogeneity studied CBMPs. This study aims to analyze changes in HRQoL patients prescribed homogenous selection CBMPs.Primary outcomes were patient-reported (PROMs) at 1, 3, 6, and 12 months from baseline. The secondary outcome was an adverse events analysis. Statistical significance defined as p < 0.050.1378 Adven® CBMPs (Curaleaf International, Guernsey, UK) included final 581 (42.16%) participants users cannabis 641 (46.51%), 235 (17.05%), 502 (36.43%) treated with oils, dried flowers, or combination two, respectively. Improvements found all PROMs each route administration baseline (p 0.010). Those flower only both oils experienced greater improvements GAD-7, SQS, EQ-5D-5L index values 0.050). There no difference between those > 3663 (265.82%) reported by 297 (21.55%) patients.There associated improvement self-reported anxiety, sleep quality, treatment formulations including most likely show clinical improvement. However, these results must be interpreted caution given limitations design.

Language: Английский

---